AAAAAA

   
Results: 1-20 |
Results: 20
IN-VITRO P24 ANTIGEN-STIMULATED LYMPHOCYTE-PROLIFERATION AND BETA-CHEMOKINE PRODUCTION IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1)-SEROPOSITIVE SUBJECTS AFTER IMMUNIZATION WITH AN INACTIVATED GP120-DEPLETEDHIV-1 IMMUNOGEN (REMUNE)
Authors: MOSS RB WALLACE MR LANZA P GIERMAKOWSKA W JENSEN FC THEOFAN G CHAMBERLIN C RICHIERI SP CARLO DJ
Citation: Rb. Moss et al., IN-VITRO P24 ANTIGEN-STIMULATED LYMPHOCYTE-PROLIFERATION AND BETA-CHEMOKINE PRODUCTION IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1)-SEROPOSITIVE SUBJECTS AFTER IMMUNIZATION WITH AN INACTIVATED GP120-DEPLETEDHIV-1 IMMUNOGEN (REMUNE), Clinical and diagnostic laboratory immunology, 5(3), 1998, pp. 308-312
A PRIMER ON HIV TYPE 1-SPECIFIC IMMUNE FUNCTION AND REMUNE(TM)
Authors: MOSS RB GIERMAKOWSKA WK SAVARY JR THEOFAN G DAIGLE AE RICHIERI SP JENSEN FC CARLO DJ
Citation: Rb. Moss et al., A PRIMER ON HIV TYPE 1-SPECIFIC IMMUNE FUNCTION AND REMUNE(TM), AIDS research and human retroviruses, 14, 1998, pp. 167-175
WHOLE-KILLED GP120-DEPLETED HIV-1 ANTIGEN IN A MURINE MODEL FOR PROPHYLACTIC VACCINATION
Authors: LANZA P MOSS RB GIERMAKOWSKA W HANCOCK RB RICHIERI SP THEOFA G JENSEN FC SALK PL CARLO DJ
Citation: P. Lanza et al., WHOLE-KILLED GP120-DEPLETED HIV-1 ANTIGEN IN A MURINE MODEL FOR PROPHYLACTIC VACCINATION, Vaccine, 16(7), 1998, pp. 727-731
CHARACTERIZATION OF HIGHLY PURIFIED, INACTIVATED HIV-1 PARTICLES ISOLATED BY ANION-EXCHANGE CHROMATOGRAPHY
Authors: RICHIERI SP BARTHOLOMEW R ALOIA RC SAVARY J GORE R HOLT J FERRE F MUSIL R TIAN HR TRAUGER R LOWRY P JENSEN F CARLO DJ MAIGETTER RZ PRIOR CP
Citation: Sp. Richieri et al., CHARACTERIZATION OF HIGHLY PURIFIED, INACTIVATED HIV-1 PARTICLES ISOLATED BY ANION-EXCHANGE CHROMATOGRAPHY, Vaccine, 16(2-3), 1998, pp. 119-129
T-CELL RECEPTOR PEPTIDE VACCINATION IN RHEUMATOID-ARTHRITIS - A PLACEBO-CONTROLLED TRIAL USING A COMBINATION OF V(BETA)3, V(BETA)14, AND V(BETA)17 PEPTIDES
Authors: MORELAND LW MORGAN EE ADAMSON TC FRONEK Z CALABRESE LH CASH JM MARKENSON JA MATSUMOTO AK BATHON J MATTESON EL URAMOTO KM WEYAND CM KOOPMAN WJ HECK LW STRAND V DIVELEY JP CARLO DJ NARDO CJ RICHIERI SP BROSTOFF SW
Citation: Lw. Moreland et al., T-CELL RECEPTOR PEPTIDE VACCINATION IN RHEUMATOID-ARTHRITIS - A PLACEBO-CONTROLLED TRIAL USING A COMBINATION OF V(BETA)3, V(BETA)14, AND V(BETA)17 PEPTIDES, Arthritis and rheumatism, 41(11), 1998, pp. 1919-1929
EFFECT OF IMMUNIZATION WITH AN INACTIVATED GP120-DEPLETED HIV-1 IMMUNOGEN ON BETA-CHEMOKINE AND CYTOKINE PRODUCTION IN SUBJECTS WITH HIV-1 INFECTION
Authors: MOSS RB TRAUGER RJ GIERMAKOWSKA WK TURNER JL WALLACE MR JENSEN FC RICHIERI SP FERRE F DAIGLE AE DUFFY C THEOFAN G CARLO DJ
Citation: Rb. Moss et al., EFFECT OF IMMUNIZATION WITH AN INACTIVATED GP120-DEPLETED HIV-1 IMMUNOGEN ON BETA-CHEMOKINE AND CYTOKINE PRODUCTION IN SUBJECTS WITH HIV-1 INFECTION, Journal of acquired immune deficiency syndromes and human retrovirology, 14(4), 1997, pp. 343-350
HIV-1-SPECIFIC FUNCTIONAL IMMUNE MEASUREMENTS AS MARKERS OF DISEASE PROGRESSION
Authors: MOSS RB RICHIERI SP FERRE F DAIGLE AE TRAUGER R THEOFAN G GIERMAKOWSKA W LANZA P BROSTOFF S CARLO DJ JENSEN FC
Citation: Rb. Moss et al., HIV-1-SPECIFIC FUNCTIONAL IMMUNE MEASUREMENTS AS MARKERS OF DISEASE PROGRESSION, Journal of biomedical science, 4(4), 1997, pp. 127-131
CROSS-CLADE IMMUNE-RESPONSES AFTER IMMUNIZATION WITH A WHOLE-KILLED GP120-DEPLETED HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IMMUNOGEN IN INCOMPLETE FREUNDS-ADJUVANT (HIV-1 IMMUNOGEN, REMUNE(TM)) IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 SEROPOSITIVE SUBJECTS
Authors: MOSS RB GIERMAKOWSKA W LANZA P TURNER JL WALLACE MR JENSEN FC THEOFAN G RICHIERI SP CARLO DJ
Citation: Rb. Moss et al., CROSS-CLADE IMMUNE-RESPONSES AFTER IMMUNIZATION WITH A WHOLE-KILLED GP120-DEPLETED HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IMMUNOGEN IN INCOMPLETE FREUNDS-ADJUVANT (HIV-1 IMMUNOGEN, REMUNE(TM)) IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 SEROPOSITIVE SUBJECTS, Viral immunology, 10(4), 1997, pp. 221-228
RESULTS OF A PHASE-I CLINICAL-TRIAL OF A T-CELL RECEPTOR VACCINE IN PATIENTS WITH MULTIPLE-SCLEROSIS .2. COMPARATIVE-ANALYSIS OF TCR UTILIZATION IN CSF T-CELL POPULATIONS BEFORE AND AFTER VACCINATION WITH A TCRV-BETA-6 CDR2 PEPTIDE
Authors: GOLD DP SMITH RA GOLDING AB MORGAN EE DAFASHY T NELSON J SMITH L DIVELEY J LAXER JA RICHIERI SP CARLO DJ BROSTOFF SW WILSON DB
Citation: Dp. Gold et al., RESULTS OF A PHASE-I CLINICAL-TRIAL OF A T-CELL RECEPTOR VACCINE IN PATIENTS WITH MULTIPLE-SCLEROSIS .2. COMPARATIVE-ANALYSIS OF TCR UTILIZATION IN CSF T-CELL POPULATIONS BEFORE AND AFTER VACCINATION WITH A TCRV-BETA-6 CDR2 PEPTIDE, Journal of neuroimmunology, 76(1-2), 1997, pp. 29-38
EFFECT OF IMMUNIZATION WITH AN INACTIVATED GP120 DEPLETED HIV-1 IMMUNOGEN (REMUNE(TM) ON BETA-CHEMOKINE AND CYTOKINE PRODUCTION IN SUBJECTSWITH HIV-1 INFECTION
Authors: MOSS RB TRAUGER RJ GIERMAKOWSKA WK TURNER JL WALLACE MR RICHIERI SP FERRE F DAIGLE AE DUFFY C THEOFAN G CARLO DJ JENSEN FC
Citation: Rb. Moss et al., EFFECT OF IMMUNIZATION WITH AN INACTIVATED GP120 DEPLETED HIV-1 IMMUNOGEN (REMUNE(TM) ON BETA-CHEMOKINE AND CYTOKINE PRODUCTION IN SUBJECTSWITH HIV-1 INFECTION, Journal of allergy and clinical immunology, 99(1), 1997, pp. 193-193
INITIAL STUDIES ON ACTIVE IMMUNIZATION OF HIV-INFECTED SUBJECTS USINGA GP120-DEPLETED HIV-1 IMMUNOGEN - LONG-TERM FOLLOW-UP
Authors: LEVINE AM GROSHEN S ALLEN J MUNSON KM CARLO TJ DAIGLE AE FERRE F JENSEN FC RICHIERI SP TRAUGER RJ PARKER JW SALK PL SALK J
Citation: Am. Levine et al., INITIAL STUDIES ON ACTIVE IMMUNIZATION OF HIV-INFECTED SUBJECTS USINGA GP120-DEPLETED HIV-1 IMMUNOGEN - LONG-TERM FOLLOW-UP, Journal of acquired immune deficiency syndromes and human retrovirology, 11(4), 1996, pp. 351-364
COMBINATION THERAPIES AGAINST HIV-1 INFECTION - EXPLORING THE CONCEPTOF COMBINING ANTIRETROVIRAL DRUG TREATMENTS WITH HIV-1 IMMUNE-BASED THERAPIES IN ASYMPTOMATIC INDIVIDUALS
Authors: FERRE F MOSS RB DAIGLE AE TRAUGER RJ RICHIERI SP JENSEN FC CARLO DJ
Citation: F. Ferre et al., COMBINATION THERAPIES AGAINST HIV-1 INFECTION - EXPLORING THE CONCEPTOF COMBINING ANTIRETROVIRAL DRUG TREATMENTS WITH HIV-1 IMMUNE-BASED THERAPIES IN ASYMPTOMATIC INDIVIDUALS, AIDS patient care, 10(6), 1996, pp. 357-361
V-BETA-17 T-CELL RECEPTOR PEPTIDE VACCINATION IN RHEUMATOID-ARTHRITIS- RESULTS OF PHASE-I DOSE-ESCALATION STUDY
Authors: MORELAND LW HECK LW KOOPMAN WJ SAWAY PA ADAMSON TC FRONEK Z OCONNOR RD MORGAN EE DIVELEY JP RICHIERI SP CARLO DJ BROSTOFF SW
Citation: Lw. Moreland et al., V-BETA-17 T-CELL RECEPTOR PEPTIDE VACCINATION IN RHEUMATOID-ARTHRITIS- RESULTS OF PHASE-I DOSE-ESCALATION STUDY, Journal of rheumatology, 23(8), 1996, pp. 1353-1362
VIRAL LOAD, CD4 PERCENTAGE, AND DELAYED-TYPE HYPERSENSITIVITY IN SUBJECTS RECEIVING THE HIV-1 IMMUNOGEN AND ANTIVIRAL DRUG-THERAPY
Authors: MOSS RB FERRE F LEVINE A TURNER J JENSEN FC DAIGLE AE RICHIERI SP TRUCKENBROD A TRAUGER RJ CARLO DJ SALK J
Citation: Rb. Moss et al., VIRAL LOAD, CD4 PERCENTAGE, AND DELAYED-TYPE HYPERSENSITIVITY IN SUBJECTS RECEIVING THE HIV-1 IMMUNOGEN AND ANTIVIRAL DRUG-THERAPY, Journal of clinical immunology, 16(5), 1996, pp. 266-271
RESULTS OF A PHASE-I CLINICAL-TRIAL OF A T-CELL RECEPTOR VACCINE IN PATIENTS WITH MULTIPLE-SCLEROSIS
Authors: WILSON DB SMITH RA RICHIERI SP CARLO DJ BROSTOFF SW MORGAN EE GOLD DP
Citation: Db. Wilson et al., RESULTS OF A PHASE-I CLINICAL-TRIAL OF A T-CELL RECEPTOR VACCINE IN PATIENTS WITH MULTIPLE-SCLEROSIS, Neurology, 46(2), 1996, pp. 52002-52002
VIRAL LOAD IN PERIPHERAL-BLOOD MONONUCLEAR-CELLS AS SURROGATE FOR CLINICAL PROGRESSION
Authors: FERRE F MOSS RB DAIGLE A RICHIERI SP JENSEN F CARLO DJ
Citation: F. Ferre et al., VIRAL LOAD IN PERIPHERAL-BLOOD MONONUCLEAR-CELLS AS SURROGATE FOR CLINICAL PROGRESSION, Journal of acquired immune deficiency syndromes and human retrovirology, 10, 1995, pp. 51-56
INACTIVATED HIV-1 IMMUNOGEN - IMPACT ON MARKERS OF DISEASE PROGRESSION
Authors: MOSS RB FERRE F TRAUGER R JENSEN F DAIGLE A RICHIERI SP CARLO DJ
Citation: Rb. Moss et al., INACTIVATED HIV-1 IMMUNOGEN - IMPACT ON MARKERS OF DISEASE PROGRESSION, Journal of acquired immune deficiency syndromes, 7, 1994, pp. 190000021-190000027
EFFECT OF THERAPEUTIC VACCINATION ON VIRAL BURDEN IN ASYMPTOMATIC INDIVIDUALS AS DETERMINED BY A QUANTITATIVE PCR-DNA ASSAY
Authors: FERRE F TIPPING D DAIGLE A RICHIERI SP JENSEN FC CARLO DJ SALK J
Citation: F. Ferre et al., EFFECT OF THERAPEUTIC VACCINATION ON VIRAL BURDEN IN ASYMPTOMATIC INDIVIDUALS AS DETERMINED BY A QUANTITATIVE PCR-DNA ASSAY, AIDS research and human retroviruses, 10, 1994, pp. 190000159-190000159
EFFECT OF IMMUNIZATION WITH INACTIVATED GP120-DEPLETED HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) IMMUNOGEN ON HIV-1 IMMUNITY, VIRAL-DNA, AND PERCENTAGE OF CD4 CELLS
Authors: TRAUGER RJ FERRE F DAIGLE AE JENSEN FC MOSS RB MUELLER SH RICHIERI SP SLADE HB CARLO DJ
Citation: Rj. Trauger et al., EFFECT OF IMMUNIZATION WITH INACTIVATED GP120-DEPLETED HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) IMMUNOGEN ON HIV-1 IMMUNITY, VIRAL-DNA, AND PERCENTAGE OF CD4 CELLS, The Journal of infectious diseases, 169(6), 1994, pp. 1256-1264
DEVELOPMENT AND VALIDATION OF A POLYMERASE CHAIN-REACTION METHOD FOR THE PRECISE QUANTITATION OF HIV-1 DNA IN BLOOD-CELLS FROM SUBJECTS UNDERGOING A 1-YEAR IMMUNOTHERAPEUTIC TREATMENT
Authors: FERRE F MARCHESE AL GRIFFIN SL DAIGLE AE RICHIERI SP JENSEN FC CARLO DJ
Citation: F. Ferre et al., DEVELOPMENT AND VALIDATION OF A POLYMERASE CHAIN-REACTION METHOD FOR THE PRECISE QUANTITATION OF HIV-1 DNA IN BLOOD-CELLS FROM SUBJECTS UNDERGOING A 1-YEAR IMMUNOTHERAPEUTIC TREATMENT, AIDS, 7, 1993, pp. 190000021-190000027
Risultati: 1-20 |